{"id":"atb-346-low-dose","safety":{"commonSideEffects":[{"rate":"null","effect":"Gastrointestinal upset"}]},"_chembl":{"chemblId":"CHEMBL4211107","moleculeType":"Small molecule","molecularWeight":"365.45"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By selectively inhibiting COX-2, ATB-346 low dose aims to reduce inflammation and pain while minimizing the risk of gastrointestinal side effects associated with traditional NSAIDs. This is achieved through a proprietary prodrug that is rapidly converted to its active form, allowing for targeted COX-2 inhibition.","oneSentence":"ATB-346 low dose is a nonsteroidal anti-inflammatory drug (NSAID) that selectively targets COX-2 to reduce gastrointestinal toxicity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:21:43.803Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of osteoarthritis"}]},"trialDetails":[{"nctId":"NCT03978208","phase":"PHASE2","title":"Efficacy and Safety of ATB-346 Versus Placebo in Osteoarthritis Patients","status":"COMPLETED","sponsor":"Antibe Therapeutics Inc.","startDate":"2019-03-29","conditions":"Osteoarthritis","enrollment":381}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Active comparator"],"phase":"phase_2","status":"active","brandName":"ATB-346 low dose","genericName":"ATB-346 low dose","companyName":"Antibe Therapeutics Inc.","companyId":"antibe-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ATB-346 is a small molecule being studied as a potential treatment for osteoarthritis. It is being investigated in a double-blind, placebo-controlled Phase 2B study to assess its efficacy and safety in patients with osteoarthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}